<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208705">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371020</url>
  </required_header>
  <id_info>
    <org_study_id>8373</org_study_id>
    <nct_id>NCT00371020</nct_id>
  </id_info>
  <brief_title>The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of combined 5-FU and low molecular weight heparin in infusion on the
      rate of retinal redetachment after silicone oil removal in cases of proliferative
      vitreoretinopathy (PVR).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2005</start_date>
  <completion_date type="Anticipated">July 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal redetachment rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative afferent pupillary defect</measure>
  </secondary_outcome>
  <condition>Proliferative Vitreoretinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin, 5-FU</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases with history of vitrectomy and silicone oil injection for management of PVR who
             undergo silicone oil removal

        Exclusion Criteria:

          -  any sign of retinal redetachment before silicone oil removal

          -  any sign of diabetic retinopathy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamid Ahmadieh, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <lastchanged_date>July 11, 2007</lastchanged_date>
  <firstreceived_date>August 31, 2006</firstreceived_date>
  <keyword>silicone oil</keyword>
  <keyword>PVR</keyword>
  <keyword>retinal redetachment</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>5-FU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
